Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia

Background We estimated the unit costs and cost-effectiveness of a government ART program in 45 sites in Zambia supported by the Centre for Infectious Disease Research Zambia (CIDRZ). Methods We estimated per person-year costs at the facility level, and support costs incurred above the facility level and used multiple regression to estimate variation in these costs. To estimate ART effectiveness, we compared mortality in this Zambian population to that of a cohort of rural Ugandan HIV patients receiving co-trimoxazole (CTX) prophylaxis. We used micro-costing techniques to estimate incremental unit costs, and calculated cost-effectiveness ratios with a computer model which projected results to 10 years. Results The program cost $69.7 million for 125,436 person-years of ART, or $556 per ART-year. Compared to CTX prophylaxis alone, the program averted 33.3 deaths or 244.5 disability adjusted life-years (DALYs) per 100 person-years of ART. In the base-case analysis, the net cost per DALY averted was $833 compared to CTX alone. More than two-thirds of the variation in average incremental total and on-site cost per patient-year of treatment is explained by eight determinants, including the complexity of the patient-case load, the degree of adherence among the patients, and institutional characteristics including, experience, scale, scope, setting and sector. Conclusions and Significance The 45 sites exhibited substantial variation in unit costs and cost-effectiveness and are in the mid-range of cost-effectiveness when compared to other ART programs studied in southern Africa. Early treatment initiation, large scale, and hospital setting, are associated with statistically significantly lower costs, while others (rural location, private sector) are associated with shifting cost from on- to off-site. This study shows that ART programs can be significantly less costly or more cost-effective when they exploit economies of scale and scope, and initiate patients at higher CD4 counts.

[1]  E. Marseille,et al.  The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda , 2009, Applied health economics and health policy.

[2]  R. Platt,et al.  Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa , 2005, PLoS medicine.

[3]  G. Maartens,et al.  The costs and perceived quality of care for people living with HIV / AIDS in the Western Cape Province in South Africa. , 2000 .

[4]  J. Tappero,et al.  Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study , 2008, The Lancet.

[5]  G. Maartens,et al.  Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital). , 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[6]  BOMBAY CALCUrIA,et al.  World development report 1993--investing in health. , 1993, Communicable disease report. CDR weekly.

[7]  Paul D van Helden,et al.  The global burden of tuberculosis--combating drug resistance in difficult times. , 2009, The New England journal of medicine.

[8]  B. Lindtjørn,et al.  Cost Effectiveness and Resource Allocation Open Access Cost Estimates of Hiv Care and Treatment with and without Anti-retroviral Therapy at Arba Minch Hospital in Southern Ethiopia , 2022 .

[9]  O. Galárraga,et al.  Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV , 2011, PharmacoEconomics.

[10]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[11]  R. Quick,et al.  Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members , 2005, AIDS.

[12]  Dean T. Jamison,et al.  World development report 1993 : investing in health , 1993 .

[13]  Milton C Weinstein,et al.  Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. , 2006, The New England journal of medicine.

[14]  D. Cm.  Persistence with drug therapy: a practical approach using administrative claims data. , 2001 .

[15]  L. Say,et al.  Maternal mortality in 2005 : estimates developed by WHO, UNICEF, UNFPA and the World Bank , 2008 .

[16]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[17]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[18]  T. Zwillich.  Obama administration may flat-line funding for PEPFAR , 2009, The Lancet.

[19]  D. Zannou,et al.  Costing universal access of highly active antiretroviral therapy in Benin , 2008, AIDS care.

[20]  Rishi Sikka,et al.  Estimating medication persistency using administrative claims data. , 2005, The American journal of managed care.

[21]  B. Chi,et al.  Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. , 2007, JAMA.

[22]  G. Kombe,et al.  Scaling up antiretroviral treatment in the public sector in Nigeria: a comprehensive analysis of resource requirements. , 2004 .

[23]  D. Mcintyre,et al.  Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. , 2004 .

[24]  D. Jamison,et al.  Disease control priorities in developing countries, second edition , 2006 .

[25]  K. Smyth,et al.  Cost Effectiveness of Facility-Based Care, Home-Based Care and Mobile Clinics for Provision of Antiretroviral Therapy in Uganda , 2012, PharmacoEconomics.

[26]  Tiaji Salaam-Blyther.  President's Emergency Plan for AIDS Relief (PEPFAR): Funding Issues After a Decade of Implementation, FY2004-FY2013 [October 10, 2012] , 2012 .

[27]  G. Kombe,et al.  The human and financial resource requirements for scaling up HIV / AIDS services in Ethiopia. , 2005 .

[28]  R. Wood,et al.  Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. , 2002, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[29]  Christopher,et al.  Persistence with drug therapy: a practical approach using administrative claims data. , 2001, Managed care.

[30]  N. Nattrass,et al.  The cost of HIV prevention and treatment interventions in South Africa , 2003 .

[31]  R. Baltussen,et al.  Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries , 2005, BMJ : British Medical Journal.